⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21345128 | 1.00 | — | — | |
| SCHEMBL13618663 | 1.00 | — | — | |
| SCHEMBL13213464 | 0.82 | — | — | |
| SCHEMBL31267174 | 0.81 | GABRP (0.42) | — | |
| SCHEMBL14660183 | 0.81 | — | — | |
| SCHEMBL23897859 | 0.81 | GABRP (0.42) | — | |
| SCHEMBL12937988 | 0.81 | GABRP (0.42) | — | |
| SCHEMBL24994838 | 0.79 | — | — | |
| SCHEMBL10046227 | 0.78 | — | — | |
| SCHEMBL12863852 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365577-A1 | Photodynamic Therapy and Diagnosis | RMW CHO GROUP LIMITED (HK) | 2023-11-16 | — | — | US | disclosed |
| WO-2023086557-A1 | NUCLEOSIDES FOR THE TREATMENT OF DNA VIRUS INFECTIONS | EMORY UNIVERSITY (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2022174179-A9 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2023-02-02 | — | — | WO | disclosed |
| US-20230023559-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC (US) | 2023-01-26 | — | — | US | disclosed |
| US-11406642-B2 | DNP and DNP prodrug treatment of neuromuscular, neurodegenerative, autoimmune, developmental, traumatic brain injury, concussion, dry eye disease, hearing loss and/or metabolic diseases | MITOCHON PHARMACEUTICALS, INC. (US) | 2022-08-09 | — | — | US | disclosed |
| US-11331331-B2 | N4-hydroxycytidine and derivatives and anti-viral uses related thereto | EMORY UNIVERSITY (US) | 2022-05-17 | — | — | US | disclosed |
| US-20220016153-A1 | N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-01-20 | — | — | US | disclosed |
| US-11197882-B2 | — | — | 2021-12-14 | — | — | US | disclosed |
| US-11147826-B2 | — | — | 2021-10-19 | — | — | US | disclosed |
| US-20210308168-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-10-07 | — | — | US | disclosed |
| US-20130209494-A1 | ENEDIYNE COMPOUNDS, CONJUGATES THEREOF, AND USES AND METHODS THEREFOR | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130165641-A1 | 6,11-BRIDGED BIARYL MACROLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-8354383-B2 | 6,11-bridged biaryl macrolides | ENANTA PHARMACEUTICALS, INC. (US) | 2013-01-15 | — | — | US | disclosed |
| US-8273720-B2 | 6,11-bicyclolides: bridged biaryl macrolide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| US-20120122943-A1 | Melampomagnolide B Derivatives as Antileukemic and Cytotoxic Agents | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2012-05-17 | — | — | US | disclosed |
| US-20090270457-A1 | 6,11-BICYCLOLIDES: BRIDGED BIARYL MACROLIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090264380-A1 | 6,11-BRIDGED BIARYL MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090118506-A1 | 6,11-BRIDGED BIARYL MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2009-05-07 | — | — | US | disclosed |
| WO-2009039177-A1 | 6, 11-BICYCLOIDES: BRIDGED BIARYL MACROLIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2009-03-26 | — | — | WO | disclosed |
| US-20090075915-A1 | 6,11-BICYCLOLIDES: BRIDGED BIARYL MACROLIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-03-19 | — | — | US | disclosed |